Skip to content

Alkermes ALKS PP&E (Net)

PP&E (Net) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.66B+6.2%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$203.1M+13.5%
AbbVie logo
AbbVieABBV
$5.69B+8.6%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$567K-26.6%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$142.4M+38.4%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$90.9M+4.5%

Segments

By geography

See full
US$226.65M
IE$918K

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's PP&E (net)?
Alkermes (ALKS) reported PP&E (net) of $220.59M in Q1 2026.
How has Alkermes's PP&E (net) changed year-over-year?
Alkermes's PP&E (net) decreased by 5.7% year-over-year, from $233.92M to $220.59M.
What is the long-term trend for Alkermes's PP&E (net)?
Over 5 years (2020 to 2025), Alkermes's PP&E (net) has grown at a -8.7% compound annual growth rate (CAGR), from $350M to $221.72M.
What does PP&E (net) mean?
This represents the net book value of long-term tangible assets, such as manufacturing facilities, laboratory equipment, and office infrastructure, after accounting for accumulated depreciation. It reflects the company's investment in the physical capacity required to conduct research and manufacture products. This metric is essential for understanding the capital intensity of the business model.